The devices and methods described herein are in the field of vascular closure.
Endovascular procedures are an increasingly common alternative to open surgical procedures. Conducted from the interior of a blood vessel, endovascular procedures can be performed under local anesthesia with no (or partial) cardiac bypass, and require a shorter hospitalization than open surgical procedures. Prior to or during an endovascular procedure, access to the vasculature is obtained via one or more arteriotomies or other openings formed in the wall of a blood vessel, and one or more catheters or other treatment devices may be advanced therethrough into the vasculature.
Some endovascular procedures, especially those designed to treat the heart or large blood vessels such as the aorta, may require large-French vascular access. For example, treatment devices used in endovascular aneurysm repair procedures (treating abdominal or thoracic aortic aneurysms by delivery of a stent graft or other graft thereto) and endovascular aortic valve replacement generally range in size from about 12 Fr (about 4 mm) to about 30 Fr (about 10 mm). Accordingly, any vascular access point (e.g., the arteriotomy or other vessel opening) must be large enough to accommodate these large-French treatment devices, and thus vascular access is usually obtained through the common femoral artery or one of the iliac arteries (e.g., the common iliac artery, the external iliac artery, or the internal iliac artery). Manual pressure is usually insufficient to close such large-French openings, and instead these openings are typically closed using one or more sutures or suture-based devices. This generally requires the presence of a surgeon in an operating room, and often requires placing the patient under general anesthesia. Accordingly, it may be desirable to provide improved methods of closing large-French vessel openings in a manner that does not require the presence of a surgeon.
Described here are devices and methods for closing one or more openings in a vessel wall. In some variations of the devices described here, the device comprises a stent graft, wherein the stent graft comprises a stent framework comprising a first axial segment and a graft material at least partially covering the stent framework, and wherein the first axial segment comprises a first access port in a side of the stent framework, and wherein the first access port is sized and configured to receive a treatment device therethrough. In some of these variations the first axial segment may comprise a first saddle-shaped ring, and wherein the first saddle-shaped ring defines the first access port. In some of these variations, the first axial segment comprises a second saddle-shaped ring, and wherein the second saddle-shaped ring defines a second access port. In other variations, the stent framework may comprise a second axial segment, wherein the second axial segment comprises at least one access port. In some of these variations, the second axial segment may comprise at least one saddle-shaped rings. The access ports may be sized and shaped to receive any suitable treatment devices or catheters. In some variations, the first access port may be sized and shaped to receive a treatment device having a diameter of at least about 5 French therethrough. In other variations, the first access port may be sized and shaped to receive a treatment device having a diameter of at least about 7 French therethrough. In other variations, the first access port may be sized and shaped to receive a treatment device having a diameter of at least about 8 French therethrough. In still other variations, the first access port may be sized and shaped to receive a treatment device having a diameter of at least about 15 French therethrough. In yet other variations, the first access port may be sized and shaped to receive a treatment device having a diameter of at least about 20 French therethrough. In some of these variations, the first access port may be sized and shaped to receive a treatment device having a diameter of about 22 French therethrough.
The stent grafts may comprise any suitable material or materials. In some variations, the stent framework may comprise a nickel-titanium alloy or other shape memory alloy. In other variations, the stent framework may comprise one or more biodegradable polymers. In some variations, the graft material may comprise polytetrafluoroethylene or expanded polytetrafluoroethylene. In some of these variations, the stent framework may be cut from a tubular piece of material. In some of these variations, the stent framework may be laser cut from the tubular piece of material. The stent graft may have any suitable dimensions. In some variations, the stent graft may have a diameter at least about 6 mm. In other variations, the stent graft may have a diameter greater at least about 7 mm.
In some variations, the stent framework may comprise a second axial segment at a first end of the stent framework, and a third axial segment at a second end of the stent frame. In some of these variations, the stent framework may be sized and shaped such that the second axial segment is configured to engage the blood vessel upstream of the opening and such that the third axial segment is configured to engage the blood vessel downstream of the opening. In some of these variations the stent framework may comprise a fourth axial segment positioned between the second and third axial segments. In some of these variations, the fourth axial segment may comprise one or more access ports.
The graft material may cover any suitable portion of the stent framework. In some variations, the graft material may entirely cover an outer surface of the stent framework. In some variations where the stent framework comprises a first axial segment, a second axial segment at a first end of the stent framework and a third axial segment at a second end of the stent framework., the graft material may cover an outer surface of the first axial segment, partially cover an outer surface of the second axial segment, and partially cover an outer surface of the third axial segment. In variations where one or more axial segments comprises an access port, the graft material may cover all or some of the access port. In variations where the graft material covers an access port, entry into the stent graft through access port may comprise puncturing, piercing, or otherwise penetrating the graft material.
Also described here are methods of closing one or more blood vessels. In some variations, a method of closing an opening in the common femoral artery, external iliac artery, internal iliac artery, or common iliac artery, may comprise advancing a introducer sheath to a position upstream of the opening, wherein the introducer sheath comprises an expandable member, expanding the expandable member to occlude blood flow past the expandable member, and advancing a delivery catheter through the introducer sheath to a position near the opening; and delivering a closure device to close the opening. In some variations, the method may further comprise introducing a dilator into a contralateral femoral artery and advancing the dilator into the common iliac artery, and wherein advancing the introducer sheath comprises advancing the introducer sheath over the dilator. In some variations, the closure device may comprise a stent graft, wherein the stent graft may comprise a stent framework having a first axial segment and a graft material at least partially covering the stent framework, and wherein the first axial segment may comprise an access port in a side of the stent framework, the first access port is sized and configured to receive a treatment device therethrough.
The expandable member may be expanded in any suitable blood vessel. In some variations, expanding the expandable member may comprises expanding the expandable member in the common iliac artery. In some variations, expanding the expandable member may comprises expanding the expandable member in the external iliac artery. In some variations, expanding the expandable member may comprises expanding the expandable member in the common femoral artery. Additionally, in some variations, the method may comprise introducing the introducer sheath into a brachial artery.
In other variations, methods for closing an opening in a blood vessel, the opening having a treatment device placed therethrough, may comprise partially withdrawing the treatment device from the blood vessel, advancing an introducer sheath to a position upstream of the opening, the introducer sheath comprising an expandable member expanding the expandable member to occlude blood flow through the blood vessel, removing the treatment device from the blood vessel; and delivering a closure device to the blood vessel to close the opening. In some of these methods, the blood vessel is the common femoral artery.
In some of variations of these methods advancing the introducer sheath may comprise advancing the introducer sheath through a contralateral femoral artery. In other variations, delivery of the closure device may comprise advancing a delivery catheter through the introducer sheath, and delivering the closure device from the delivery sheath. In some of these variations, the closure device may comprise a stent graft, the stent graft comprising a stent framework having a first axial segment and a graft material at least partially covering the stent framework, and wherein the first axial segment comprises an access port in a side of the stent framework, the first access port is sized and configured to receive a treatment device therethrough. In some of these variations, the method further comprises aligning the stent graft such that the first access port is placed adjacent to the opening.
Described here are devices and methods for closing one or more openings in a vessel wall. Specifically, the devices described here comprise one or more stent grafts. The stent graft may comprise a graft material and a generally-cylindrical stent framework having one or more axial segments. At least one of the axial segments may define an access port in a side of the stent framework, which may allow a catheter or treatment device to be inserted through a side of the stent graft.
Also described here are methods for closing one or more openings in a blood vessel. Generally these methods comprise placing an introducer sheath comprising a balloon or other expandable member upstream of the vascular opening, and temporarily occluding blood flow with the balloon. In variations where the vascular opening is in the common femoral artery, placing the introducer sheath may comprise inserting the introducer sheath into the contralateral common femoral artery, and advancing the introducer sheath up the contralateral iliac artery and into the ipsilateral iliac artery. A delivery catheter or other device may be advanced through the introducer sheath, and may be used to close the vascular opening. In some variations, this comprises delivering one or more stent grafts, such as the stent grafts described hereinthroughout, adjacent the opening to close or otherwise seal off the opening. In some instances, the methods described here may be utilized to close or seal one or more large-French openings (e.g., greater than about 10 Fr (about 3.3 mm)).
The devices described here may comprise one or more stent grafts, which may comprise a stent framework and a graft material at least partially covering the stent framework. The stent grafts are generally cylindrical in shape, and may define one or more lumens along the longitudinal axis of the stent graft, such that blood may flow therethrough when the stent graft is placed in a blood vessel. The stent framework of the stent grafts described here generally comprise one or more axial segments, where at least one of the axial segments defines an access port, which may allow for re-entry into a vessel through a side of the stent graft, as will be described in more detail below. The stent grafts described here are generally expandable between a low-profile delivery configuration and an expanded deployed configuration for apposition against tissue. The stent grafts may be self-expandable, or may be expanded by a balloon or other expandable structure.
As shown in
Each axial segment of the stent framework may have any suitable configuration. At least one of the axial segments may comprise one or more access ports. Generally, an access port provides an aperture or space in a side of the stent framework through which a needle, catheter, or other treatment device may be inserted without dislodging, damaging, or permanently deforming the stent frame. For example, in the variation of stent graft (100) described above in relation to
The aperture (118) of the saddle-shaped ring (114) may act as an access port (116) in a side of stent graft (100) through which one or more needles, catheters, or treatment devices may be inserted. For example, in some instances stent graft (100) may be placed inside of a blood vessel (120) (e.g., the common femoral artery), as shown in
Each access port of the stent grafts described here may be partially or fully covered by the graft material, as will be described in more detail below. For example, in the variation of stent graft (100) described above in relation to
The stent framework may comprise any number of access ports (e.g., one, two, three, four, five, or six or more). In variations where the stent framework has a single access port, one axial segment may comprise a single access port. In variations where the stent framework comprises multiple access ports, a single axial segment may comprise all of the access ports, or multiple axial segments may comprise one or more access ports. For example, in the variation of stent graft (100) described above in
In some variations, an access port may comprise one or more deflectable members. For example,
In some variations, the stent framework may comprise one or more axial segments that do not comprise an access port. For example, in the stent framework (102) of stent graft (100) described in more detail above regarding
In variations where the stent framework comprises two or more axial segments, each segment may or may not be connected to one or more additional segments. For example, in some variations, such as stent framework (102) described above in relation to
The stent framework and components thereof may be made from any suitable material or combinations of materials. In some variations, the entire stent framework may be made from the same material. In other variations, different portions of the stent framework may be made from different materials. The stent framework (or one or more portions thereof) may be biodegradable, bioabsorbable, or otherwise erodible, but need not be.
In some variations, one or more portions of the stent framework may comprise a shape-memory material. In some of these variations, one or more portions of the stent framework may comprise a nickel-titanium alloy (nitinol). Additionally or alternatively, one or more portions of the stent framework may comprise a copper-aluminum-nickel alloy, a copper-zinc-aluminum-nickel alloy, a shape memory alloys comprising zing, copper, gold, and/or iron, and combinations thereof. In some variations, one or more portions of the stent framework may comprise one or more polymers. Examples of suitable polymers include, but are not limited to, aliginate, cellulose, dextran, elastin, fibrin, hyaluronic acid, polyacetals, polyarylates (L-tyrosine-derived or free acid), poly(α-hydroxy-esters), poly(β-hydroxy-esters), polyamides, poly(amino acid), polyalkanotes, polyalkylene alkylates, polyalkylene oxylates, polyalkylene succinates, polyanhydrides, polyanhydride esters, polyaspartimic acid, polybutylene diglycolate, poly(caprolactone), poly(caprolactone)/poly(ethylene glycol)copolymers, poly(carbonate), L-tyrosine-derived polycarbonates, polycyanoacrylates, polydihidropyrans, poly(dioxanone), poly-p-dioxanone, poly(epsilon-caprolactone), poly(epsilon-caprolactone-dimethyltrimethylene carbonate), poly(esteramide), poly(esters), aliphatic polyesters, poly(etherester), poly(ethylene glycol)/poly(orthoester)copolymers, poly(glutarunic acid), poly(glycolic acid), poly(glycolide), poly(glycolide)/poly(ethylene glycol)copolymers, poly(glycolide-trimethylene carbonate), poly(hydroxyalkanoates), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), poly(imino carbonates), polyketals, poly(lactic acid), poly(lactic acid-co-glycolic acid), poly(lactic acid-co-glycolic acid)/poly(ethylene glycol)copolymers, poly(lactide), poly(lactide-co-caprolactone), poly(DL-lactide-co-glycolide), poly(lactide-co-glycolide)/poly(ethylene glycol)copolymers, poly(lactide)/poly(ethylene glycol)copolymers, poly(lactide)/poly(glycolide)copolymers, polyorthoesters, poly(oxyethylene)/poly(oxypropylene)copolymers, polypeptides, polyphosphazenes, polyphosphoesters, polyphosphoester urethanes, poly(propylene fumarate-co-ethylene glycol), poly(trimethylene carbonate), polytyrosine carbonate, polyurethane, PorLastin or silk-ealastin polymers, spider silk, tephaflex, terpolymer(copolymers of glycolide,lactide or dimethyltrimethylene carbonate), and combinations, mixtures or copolymers thereof. Other suitable materials suitable for use in the stent framework include, but are not limited to, stainless steel, gold, tantalum, platinum, tungsten, niobium, ceramic, cobalt-chromium alloys, magnesium, aluminum, carbon fiber, combinations thereof and the like.
As mentioned above, the stent grafts described here generally comprise a graft material at least partially covering the stent framework. In some variations, the graft material covers the entire stent framework (e.g., both an interior and exterior surfaces of the stent framework). In some variations, such as stent graft (100) described in more detail above with respect to
In variations where an axial segment comprises an access port, the graft material may fully or partially cover access port. In variations where the graft material covers an access port, entry into the stent graft through the access port (e.g., with a needle, catheter, or treatment device) may comprise puncturing, piercing, or otherwise penetrating the graft material. In some variations, the graft material may comprise one or more apertures or openings which may allow access through access port.
The graft material may be attached to the stent framework in any suitable manner. In some variations, the graft material may be bonded to, laminated on, or otherwise attached to a portion of the stent framework via one or more adhesives or chemicals. In other variations, the graft material may be attached to one or more portions of the stent framework via one or more mechanical attachment mechanisms such as a clip. In still other variations, the graft material may be sutured to one or more portions of the stent framework. In other variations, one or more portions of the stent framework may be sewn or otherwise contained in one or more pockets defined between two sections of graft material. In yet other variations, one or more stent members may be positioned to at least partially circumscribe the stent graft, and may act to hold the graft material in contact with the stent framework.
The graft material may or may not be biodegradable, bioabsorbable or otherwise erodible, and may be made from any suitable material or combination of materials. In some variations, at least a portion of the graft may be woven or braided. In these variations, the graft may be woven from any suitable fiber, strand, yarn, filament, or combinations thereof. In other variations, at least a portion of the graft may be non-woven, such as, for example, a solid film, sheet, or tube. The graft material may comprise a single layer, or may comprise a plurality of layers. In variations where the graft material comprises multiple layers, the layers may be made from the same material or materials, or may be made from different materials. Additionally, multiple layers may be connected in any suitable manner (e.g., via suturing, clamping, laminating, adhesive bonding, chemical bonding, or the like).
Examples of suitable graft materials include, but are not limited to collagen, polyethylene, polypropylene, polyacrylonitrile, cellulose, nylon, Dacron, polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), polyurethane, polycarbonate-urethane, and polyethylene terepthalate. In some variations, the graft material may comprise one or more tissues or other extracellular matrixes. In some of these variations, the tissue may be derived from an autologous source. In other variations, the tissue may be derived from a xenologous source.
In some variations, one or more of portions of the graft material may comprise a coating. The graft may be coated using any suitable material, or materials, such as, for example, polyurethanes, silicones, one or more polymers (e.g., poly(ethylene glycol), poly(lactic acid), polyamides, PTFE, copolymers thereof), combinations thereof or the like. In other variations, one or more portions of the graft material may be seeded with one or more cells (e.g., one or more stem cells, one or more endothelial progenitor cells and the like.
In some variations of the devices described here, one or more portions of the stent graft (e.g., the graft material or the stent framework) may comprise one or more drugs or other bioactive agents. In some instances, one or more drugs or bioactive agents may be applied to one or more portions of the stent graft as a coating (e.g., by spray coating, dip-coating, brushing, or the like). In other variations, one or more drugs or bioactive agents may be directly incorporated into one or more portions of the stent graft, and may either diffuse therefrom or, in instances where one or more portions of the stent graft is biodegradable, may be released as those portions of stent graft biodegrade. In some variations, the graft may comprise one or more growth factors or other agents to help promote tissue ingrowth of tissue from the blood vessel. In other variations, the drug or bioactive agents may comprise one or more antipoliferative agents, one or more immunomodulating drugs, one or more antisclerosing agents, one or more anti-angiogenic agents, one or more thromobresistent agents, one or more anti-inflammatory agents, one or more genetic agents, one or more cell-regulating agents, derivatives, homologs, pharmaceutical salts, and combinations thereof.
As mentioned above, the stent graft may comprise one or more markers. These markers may be any suitable material capable of being viewed indirectly (e.g., via fluoroscopy, ultrasound, or the like). In some instances, one or more portions of the stent framework may be coated with or may otherwise comprises a radiopaque or echogenic material. Examples of suitable echogenic materials include, but are not limited to, barium sulfate, zirconium dioxide, cadmium, tungsten, gold, tantalum, bismusth, platinum, iridum, rhodium, or the like. In other variations, one or more radiopaque markers may be attached to a portion of the stent graft.
In some variations, one or more markers may help the user determine the rotational orientation of the stent graft within the vessel. This may help a user position the stent graft within a vessel, and may also help guide a user in inserting one or more needles, catheters, or treatment devices through an access port of the stent graft, as will be described in more detail below. In the variation of stent graft (100) shown in
In variations where an axial segment comprises a single access port, it may be difficult to determine during visualization whether the access port is pointing toward or away from the visualization device. To help alleviate this difficulty, the stent graft may comprise one or more markers that may indicate the directional orientation of the access port. For example, in the variation of axial segment (300) described above in relation to
In some variations one or more markers may comprise an asymmetric shape or pattern. These asymmetric marker may comprise any suitable shape or combinations of shapes, such as, for example, one or more arrows, letters, irregular shapes or the like. In these variations, the asymmetric marker may help a user to determine the rotational alignment of the stent graft. For example, in variations where a marker comprises an arrow shape, the arrow may point in one direction (e.g., to the right or left) when an access port is directed toward a visualization device, and may point in the opposite direction when the access port is directed away from a visualization device. In other instances, one or more markers may be formed into one or more letters, which may in turn spell a word. In these variations, the word may be readable when an access port is directed toward a visualization device, and may be unreadable/mirror-flipped when the access port is directed away from a visualization device, or vice versa. It should be appreciated that the stent graft may comprise any suitable number of markers, and these markers may have any suitable positioning in or on the stent graft.
The stent graft may have any suitable dimensions. Because the stent grafts may be expandable (e.g., self-expanding, balloon-expandable, or the like), the dimensions of the stent graft may change, depending whether the device is placed in a low-profile or an expanded configuration. In some variations, the stent graft may be at least about 6 mm in diameter when in an expanded configuration. In other variations, the stent graft may be at least about 7 mm in diameter when in an expanded configuration. In other variations, the stent graft may be at least about 8 mm in diameter when in an expanded configuration. In other variations, the stent graft may be at least about 9 mm in diameter when in an expanded configuration. In other variations, the stent graft may be at least about 10 mm in diameter when in an expanded configuration. Similarly, the stent graft may have any suitable length. In some variations, the stent graft may be between about 20 mm and about 40 mm. In other variations the stent graft may be between about 20 mm and about 30 mm, between about 30 mm and about 40 mm, between about 25 mm and about 35 mm, or the like It should be appreciated that the dimensions of the stent graft may be chosen based upon the anatomy in which the stent graft will be delivered. For example, in some variations, the expanded diameter of the stent graft may be greater than the diameter of the vessel in which it will be placed, such that expansion of the stent graft within the vessel may press or hold the stent graft in place within the blood vessel.
In some variations, the stent grafts described here may comprise one or more sensors. For example, the stent grafts may comprise one or more flow or pressure sensors, such that a user may measure or otherwise determine the blood flow through the stent graft when placed in a vessel. Additionally, in some variations the stent graft may be configured to be retrievable, repositionable and/or removable after delivery to a vessel. In some variations, one or more grasping mechanisms may be used to move, remove, or otherwise reposition the stent graft. In other variations, the stent graft may comprise one or more tethers, sutures, wires or other similar structures for helping to move or reposition the stent. The tether may be pulled or otherwise manipulated (e.g., via one or more grasping mechanisms). In some variations, the tether may be at least temporarily attached to the stent framework. For example, in variations where a portion of the stent framework comprises a plurality of expandable cells, such as expandable cells (119) of stent member (117) as described above in relation to
Also described here are methods for closing one or more openings in a vessel wall. In some variations, the methods described here are used to close one or more arteriotomies or other vascular openings formed prior to or during an endovascular procedure (e.g., EVAR or endovascular aortic valve replacement). In other variations, the methods described here may be used to close or seal one or more pseudoaneurysms or other iatrogenic holes (e.g., a retroperitoneal bleed) in a blood vessel. In some variations, the methods and devices described here may be used to seal an arteriovenous fistula. Generally, the methods described here may be used to seal one or more openings in an iliac artery (the common iliac artery, the internal iliac artery, or the external iliac artery) or the common femoral artery. The methods described here may be used to close openings created by large-French catheters and treatment devices, and in some instances may be used to close vascular openings greater than about 12 Fr (about 4 mm). In other instances, the methods may be used to close a vascular opening greater than about 15 Fr (about 5 mm). In other instances, the methods may be used to close a vascular opening greater than about 20 French (about 6.67 mm). In yet other instances, the methods may be used to close a vascular opening greater than about 27 French (about 9 mm).
Generally, the methods described here comprise advancing an introducer sheath comprising a balloon or other expandable member to a position upstream of the vascular opening. Once in place, the balloon may be expanded to occlude flow through the blood vessel. In variations where a catheter or treatment device is positioned through the vascular opening, the catheter or treatment device may be removed from the vascular opening. A delivery catheter may then be advanced through the sheath to a position near the vascular opening, and one or more closure devices may be delivered to the blood vessel to seal or otherwise close the opening. The closure device may be any suitable closure device, such as one or more of the devices described above. Once the opening has been closed, this closure may then be confirmed via angiography.
To aid in understanding of some the methods described here,
Before initiating one of the closure procedures described here, it may be useful to determine and assess one or more relevant dimensions of the patient's anatomy. For example, in instances where a closure device will be placed inside of the common femoral artery, it may be desirable to measure the dimensions of the common femoral artery (e.g., the diameter of the artery and/or the length between the beginning of the common femoral artery and the bifurcation into the deep and superficial femoral arteries). Once the dimension of the common femoral artery has been determined (e.g., via angiography or the like), a user may pick a closure device that is properly sized to fit within common femoral artery.
As mentioned above, some of the methods described here may comprise sealing one or more vascular openings formed prior to or during an endovascular procedure. During these endovascular procedures, access to the vasculature is generally obtained via an opening formed in one of the common femoral arteries or one of the brachial arteries. A catheter or treatment device may be advanced through the opening, and may be further advanced to a target location to complete the endovascular procedure. Once the endovascular procedure has been completed, the opening may then be closed by one of the methods described here.
For example,
It should be appreciated that the introducer sheath (508) may be advanced in any suitable manner. In some variations, the introducer sheath (508) may be at least partially advanced over a guidewire. In other variations, one or more curved dilators may be advanced into the right common iliac artery (506), and the introducer sheath (508) may be advanced over the curved dilator. It should also e appreciated that some or all of the method may be performed under fluoroscopic, ultrasound, or x-ray guidance. The introducer sheath may have any suitable diameter (e.g., about 6 French, about 7 French, about 8 French, or the like). Similarly, the introducer sheath may have any suitable length. For example, in some instances where the introducer sheath is advanced from a contralateral femoral artery, the introducer sheath may be at least about 40 cm, at least about 45 cm, at least about 55 cm, at least about 65 cm, or the like. In some instances where the introducer sheath is advanced from a brachial artery, the introducer sheath may be at least about 80 cm, at least about 90 cm, at least about 100 cm, at least about 110 cm, or the like.
Once in place, balloon (512) may be expanded to occlude blood flow past the balloon (512), and treatment device (502) may then be removed from the opening (504), as shown in
In some variations the delivery catheter (516) may deliver or otherwise deploy a stent graft, such as one or more of the stent grafts described above. In some of these variations, the delivery catheter (516) may be advanced downstream of opening (504), at which point a first axial segment (518) of stent graft (520) may be deployed downstream of the opening (504), as shown in
Once the stent graft (520) has been deployed to close opening (504), closure may be confirmed via angiography or another suitable technique. In some variations, confirming closure of the opening (504) may comprise deflating the balloon (510). Additionally, one or more radiopaque dyes (not shown) may be introduced into the vasculature (e.g., by delivery catheter (516), introducer sheath (508), or another suitable device), and fluoroscopy may be used to look for dye leaking or otherwise passing through opening (504). Additionally, one or more treatment devices may have inadvertently formed an additional opening, cut or hole in one or more of the blood vessels, and the radiopaque dye may be used to detect these additional openings. If necessary, balloon (510) may be re-inflated, and one or more additional closure devices may be delivered through the introducer sheath (508) and/or the delivery catheter (516), to ensure closure of any of these openings. In some of these variations, delivery catheter (516) may be withdrawn through introducer sheath (508), and an second delivery catheter (not shown) may be advanced through introducer sheath (508) to deliver a second closure device (not shown). Once the opening (504) (and any other openings) have been properly closed, the introducer sheath (508) and delivery sheath may be removed from the body.
While the methods described above in relation to
This application is a divisional of U.S. patent application Ser. No. 12/938,218, filed on Nov. 2, 2010, which claims priority to U.S. Provisional Application Ser. No. 61/280,389, filed on Nov. 3, 2009, the disclosure of each of which is hereby incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
61280389 | Nov 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12938218 | Nov 2010 | US |
Child | 13667885 | US |